Investors
The next stage in the development of Disperazol is to expand our portfolio of assets to target Gram-neagitve bacteria beyond Pseudomonas.
A recent successful bid to become part of the INCATE portfolio of antibacterial therapies being developed in Europe brought Disperazol a step closer to reaching this goal.
Discussions are also welcomed with potential funders, partners and collaborators to advance Disperazol’s parallel development as a medical device with surface coating capabilities on implantable devices.
$500,000 is needed to progress Disperazol towards and expanded portfolio of assets against Gram-negative bacteria.
We welcome discussions and expression of interest from potential funders, partners and collaborators for this development stream for Disperazol.
Contact us for more information or to arrange a discussion.